Skip to main content
OCUL logo

OCUL · Ocular Therapeutix, Inc · Webcasts, Transcripts & Audio

Track OCUL — free
$5.99 +0.05 (+0.76%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.31B
Shares
220.02M
Volume · Nov 19 220.23K Avg daily vol (3M) 3.04M

Ocular Therapeutix, Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Ocular Therapeutix, Inc (OCUL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Ocular Therapeutix, Inc (OCUL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-09
Ocular Therapeutix, Inc (OCUL) Q3 2026 Earnings Call Transcript
Confident tone SOLAR trial design and primary endpoint change SOL1 Phase III superiority results Competitive landscape and differentiation
Revenue
$12.87M
▼ 11.5% YoY
Diluted EPS
$-0.42
Gross margin
88.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-10-20
Ocular Therapeutix, Inc (OCUL) October 20, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-18
Ocular Therapeutix, Inc (OCUL) Q2 2026 Earnings Call
Revenue
$13.47M
▲ 0.1% YoY
Diluted EPS
$-0.35
Gross margin
85.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-12
Ocular Therapeutix, Inc (OCUL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Ocular Therapeutix, Inc (OCUL) Q1 2026 Earnings Call Transcript
Confident tone X-Paxly SOL1 Phase 3 superiority in wet AMD SOLAR confirmatory trial NDA submission and regulatory pathway
Revenue
$10.79M
▲ 0.8% YoY
Diluted EPS
$-0.40
Gross margin
87.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Ocular Therapeutix, Inc (OCUL) Q4 2025 Earnings Call
Revenue
$13.25M*
▼ 22.4% YoY
Gross margin
88.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ocular Therapeutix, Inc (OCUL) Q3 2025 Earnings Call Transcript
Confident tone AXPAXLI superiority label strategy SOL-1 and SOL-R wet AMD registrational trials HELIOS diabetic retinopathy program
Revenue
$14.54M
▼ 5.7% YoY
Diluted EPS
$-0.38
Gross margin
87.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ocular Therapeutix, Inc (OCUL) Q2 2025 Earnings Call Transcript
Confident tone AXPAXLI registrational program / SOL trials Trial quality, retention and rescue conduct SOL-1 top-line data readout
Revenue
$13.46M
▼ 18.1% YoY
Diluted EPS
$-0.39
Gross margin
85.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Ocular Therapeutix, Inc (OCUL) Q4 2024 Earnings Call Transcript
Confident tone AXPAXLI registrational program in wet AMD SOL-R trial optimization and sample size reduction FDA SPA amendment and redosing strategy
Revenue
$17.08M*
▲ 15.4% YoY
Gross margin
92.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Ocular Therapeutix, Inc (OCUL) Q3 2024 Earnings Call Transcript
Confident tone AXPAXLI Wet AMD SOL-1 and SOL-R Trials Diabetic Retinopathy / DME Opportunity Regulatory Pathway / FDA
Revenue
$15.43M
▲ 2.3% YoY
Diluted EPS
$-0.22
Gross margin
89.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Ocular Therapeutix, Inc (OCUL) Q2 2024 Earnings Call Transcript
Confident tone SOL-1 registration study enrollment SOL-R repeat-dosing registration study FDA alignment on study designs
Revenue
$16.44M
▲ 8.3% YoY
Diluted EPS
$-0.26
Gross margin
90.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ocular Therapeutix, Inc (OCUL) Q1 2024 Earnings Call
Revenue
$14.77M
▲ 10.5% YoY
Diluted EPS
$-0.49
Gross margin
91.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-11-07
Ocular Therapeutix, Inc (OCUL) Q3 2023 Earnings Call Transcript
Revenue
$15.08M
▲ 26% YoY
Diluted EPS
$-0.25
Gross margin
90.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Ocular Therapeutix, Inc (OCUL) Q2 2023 Earnings Call Transcript
Revenue
$15.19M
▲ 23.8% YoY
Diluted EPS
$-0.26
Gross margin
91.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Ocular Therapeutix, Inc (OCUL) Q1 2023 Earnings Call Transcript
Revenue
$13.37M
▲ 1.4% YoY
Diluted EPS
$-0.39
Gross margin
90.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ocular Therapeutix, Inc (OCUL) Q4 2022 Earnings Call Transcript
Revenue
$14.08M*
▲ 14.4% YoY
Gross margin
92.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ocular Therapeutix, Inc (OCUL) Q3 2022 Earnings Call Transcript
Revenue
$11.96M
▼ 1.5% YoY
Diluted EPS
$-0.31
Gross margin
91.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ocular Therapeutix, Inc (OCUL) Q2 2022 Earnings Call Transcript
Revenue
$12.27M
▲ 4.7% YoY
Diluted EPS
$-0.25
Gross margin
90.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Ocular Therapeutix, Inc (OCUL) Q1 2022 Earnings Call Transcript
Revenue
$13.19M
▲ 79.6% YoY
Diluted EPS
$-0.22
Gross margin
90.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Ocular Therapeutix, Inc (OCUL) Q4 2021 Earnings Call Transcript
Revenue
$12.31M*
▲ 67.5% YoY
Gross margin
91.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Ocular Therapeutix, Inc (OCUL) Q3 2021 Earnings Call Transcript
Revenue
$12.15M
▲ 106.8% YoY
Diluted EPS
$-0.23
Gross margin
89.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Ocular Therapeutix, Inc (OCUL) Q2 2021 Earnings Call Transcript
Revenue
$11.72M
▲ 646.8% YoY
Diluted EPS
$-0.25
Gross margin
90.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Ocular Therapeutix, Inc (OCUL) Q1 2021 Earnings Call Transcript
Revenue
$7.34M
▲ 181.4% YoY
Diluted EPS
$-0.24
Gross margin
87.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Ocular Therapeutix, Inc (OCUL) Q4 2020 Earnings Call Transcript
Revenue
$7.35M*
▲ 225.8% YoY
Gross margin
90.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ocular Therapeutix, Inc (OCUL) Q3 2020 Earnings Call Transcript
Revenue
$5.88M
▲ 608.8% YoY
Diluted EPS
$-0.21
Gross margin
92.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-17
Ocular Therapeutix, Inc (OCUL) Q2 2020 Earnings Call Transcript
Revenue
$1.57M
▲ 141.4% YoY
Diluted EPS
$-0.64
Gross margin
91.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Ocular Therapeutix, Inc (OCUL) Q1 2020 Earnings Call Transcript
Revenue
$2.61M
▲ 430.3% YoY
Diluted EPS
$-0.41
Gross margin
68.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–28 of 28 webcasts
Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 269 filings 250 filers Visit website Investor relations